Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.

Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, Dhar A, Karpinich N, Tian L, Tyler DS, MacPherson L, Shi J, Pinnawala N, Yew Fong C, Papenfuss AT, Grimmond SM, Dawson SJ, Allan RS, Kruger RG, Vakoc CR, Goode DL, Naik SH, Gilan O, Lam EYN, Marine JC, Prinjha RK, Dawson MA.

Nat Commun. 2019 Jun 20;10(1):2723. doi: 10.1038/s41467-019-10652-9.

PMID:
31222014
2.

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.

Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, Grimes HL, Roboz GJ, Kruger RG, Creasy CL, Paietta EM, Levine RL, Carroll M, Melnick AM.

Cancer Discov. 2019 May 10. doi: 10.1158/2159-8290.CD-19-0106. [Epub ahead of print]

PMID:
31076479
3.

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.

Mohammad HP, Barbash O, Creasy CL.

Nat Med. 2019 Mar;25(3):403-418. doi: 10.1038/s41591-019-0376-8. Epub 2019 Mar 6. Review.

PMID:
30842676
4.

Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.

Lee C, Rudneva VA, Erkek S, Zapatka M, Chau LQ, Tacheva-Grigorova SK, Garancher A, Rusert JM, Aksoy O, Lea R, Mohammad HP, Wang J, Weiss WA, Grimes HL, Pfister SM, Northcott PA, Wechsler-Reya RJ.

Nat Commun. 2019 Jan 18;10(1):332. doi: 10.1038/s41467-018-08269-5.

5.

Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis.

Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, Duy C, Shen H, Vidal MNC, Baslan T, Mohammad HP, Kruger RG, Shaknovich R, Haberman AM, Inghirami G, Lowe SW, Melnick AM.

Nat Immunol. 2019 Jan;20(1):86-96. doi: 10.1038/s41590-018-0273-1. Epub 2018 Dec 10.

6.

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

Smitheman KN, Severson TM, Rajapurkar SR, McCabe MT, Karpinich N, Foley J, Pappalardi MB, Hughes A, Halsey W, Thomas E, Traini C, Federowicz KE, Laraio J, Mobegi F, Ferron-Brady G, Prinjha RK, Carpenter CL, Kruger RG, Wessels L, Mohammad HP.

Haematologica. 2019 Jun;104(6):1156-1167. doi: 10.3324/haematol.2018.199190. Epub 2018 Dec 4.

7.

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA.

Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16.

8.

Targeting Histone Methylation in Cancer.

McCabe MT, Mohammad HP, Barbash O, Kruger RG.

Cancer J. 2017 Sep/Oct;23(5):292-301. doi: 10.1097/PPO.0000000000000283. Review.

PMID:
28926430
9.

Antitumor activity of LSD1 inhibitors in lung cancer.

Mohammad HP, Kruger RG.

Mol Cell Oncol. 2016 Jan 6;3(2):e1117700. doi: 10.1080/23723556.2015.1117700. eCollection 2016 Mar.

10.

Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.

Van Aller GS, Graves AP, Elkins PA, Bonnette WG, McDevitt PJ, Zappacosta F, Annan RS, Dean TW, Su DS, Carpenter CL, Mohammad HP, Kruger RG.

Structure. 2016 May 3;24(5):774-781. doi: 10.1016/j.str.2016.03.010. Epub 2016 Apr 7.

11.

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter CL, Johnson NW, Hann CL, Kruger RG.

Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002.

12.

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.

13.

DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes.

Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, Baylin SB.

Nucleic Acids Res. 2012 May;40(10):4334-46. doi: 10.1093/nar/gks031. Epub 2012 Jan 25.

14.

Loss of a single Hic1 allele accelerates polyp formation in Apc(Δ716) mice.

Mohammad HP, Zhang W, Prevas HS, Leadem BR, Zhang M, Herman JG, Hooker CM, Watkins DN, Karim B, Huso DL, Baylin SB.

Oncogene. 2011 Jun 9;30(23):2659-69. doi: 10.1038/onc.2010.633. Epub 2011 Feb 7.

15.

Linking cell signaling and the epigenetic machinery.

Mohammad HP, Baylin SB.

Nat Biotechnol. 2010 Oct;28(10):1033-8. doi: 10.1038/nbt1010-1033.

PMID:
20944593
16.

Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells.

Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, Briggs KJ, Zhang W, Argani P, Simons B, Yu W, Matsui W, Van Criekinge W, Rassool FV, Zambidis E, Schuebel KE, Cope L, Yen J, Mohammad HP, Cheng L, Baylin SB.

Cancer Res. 2010 Oct 1;70(19):7662-73. doi: 10.1158/0008-5472.CAN-10-1361. Epub 2010 Sep 14.

17.

Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.

Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG, Carraway HE.

Leuk Lymphoma. 2010 Sep;51(9):1711-9. doi: 10.3109/10428194.2010.496505.

18.

Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus.

Easwaran HP, Van Neste L, Cope L, Sen S, Mohammad HP, Pageau GJ, Lawrence JB, Herman JG, Schuebel KE, Baylin SB.

Cancer Res. 2010 Oct 15;70(20):8015-24. doi: 10.1158/0008-5472.CAN-10-0765. Epub 2010 Aug 24.

19.

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.

Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG, Carraway HE.

Epigenetics. 2010 Oct 1;5(7):590-600. Epub 2010 Oct 1.

20.

Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation.

Mohammad HP, Cai Y, McGarvey KM, Easwaran H, Van Neste L, Ohm JE, O'Hagan HM, Baylin SB.

Cancer Res. 2009 Aug 1;69(15):6322-30. doi: 10.1158/0008-5472.CAN-09-0065. Epub 2009 Jul 14.

21.

Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island.

O'Hagan HM, Mohammad HP, Baylin SB.

PLoS Genet. 2008 Aug 15;4(8):e1000155. doi: 10.1371/journal.pgen.1000155.

22.

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing.

Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, Baylin SB.

Nat Genet. 2007 Feb;39(2):237-42. Epub 2007 Jan 9.

23.
24.

Targeted overexpression of luteinizing hormone causes ovary-dependent functional adenomas restricted to cells of the Pit-1 lineage.

Mohammad HP, Abbud RA, Parlow AF, Lewin JS, Nilson JH.

Endocrinology. 2003 Oct;144(10):4626-36. Epub 2003 Jul 17.

PMID:
12960102

Supplemental Content

Loading ...
Support Center